Canadian Cancer Trials Group

Canadian Cancer Trials Group
Name	Canadian Cancer Trials Group
Formation	1970s
Type	Clinical trials cooperative group
Headquarters	Queen's University, Kingston, Ontario
Region served	Canada, international
Leader title	Director

Canadian Cancer Trials Group

The Canadian Cancer Trials Group operates as a national clinical trials cooperative group based at Queen's University in Kingston, Ontario that designs, coordinates, and conducts multicentre oncology trials across Canada and internationally. It works with academic centres such as Princess Margaret Cancer Centre, BC Cancer, and Montreal General Hospital while partnering with regulatory bodies like Health Canada and funding agencies including Canadian Institutes of Health Research, Cancer Research UK, and philanthropic organizations such as Canadian Cancer Society and Canadian Cancer Society Research Institute. The Group has influenced clinical practice through trials involving agents approved by regulators including the United States Food and Drug Administration, the European Medicines Agency, and national health technology assessment bodies like CADTH.

History

The Group traces origins to cooperative oncology initiatives in the 1970s linked to programs at University of Toronto, McGill University, University of British Columbia, and Dalhousie University. Early collaborations involved investigators from Ottawa Hospital Research Institute and University of Alberta to address treatment questions in hematology and solid tumours. Over decades the Group expanded governance structures influenced by models from EORTC, ALLIANCE for Clinical Trials in Oncology, and SWOG. Key historical milestones included adopting Good Clinical Practice standards aligned with International Council for Harmonisation guidelines and implementing centralized data management using approaches developed at Mayo Clinic and MD Anderson Cancer Center.

Organization and Governance

The Group is hosted within academic administrative frameworks at Queen's University and governed by a board comprising clinicians from centres such as St. Michael's Hospital, Sunnybrook Health Sciences Centre, Hamilton Health Sciences, and London Health Sciences Centre. Scientific direction is provided by disease-specific committees representing fields including medical oncology at University Health Network, radiation oncology at Toronto General Hospital, surgical oncology at Vancouver General Hospital, and hematology at The Ottawa Hospital. Regulatory compliance intersects with agencies like Health Canada and ethics oversight from Research Ethics Boards at institutions such as Université de Montréal, University of Calgary, and Western University.

Research Programs and Clinical Trials

Programs span breast cancer trials involving investigators from Sunnybrook Odette Cancer Centre and Mount Sinai Hospital (Toronto), gastrointestinal oncology trials with teams at Vancouver General Hospital and Jewish General Hospital (Montreal), lung cancer studies from Princess Margaret Hospital and BC Cancer Vancouver, and hematologic malignancy trials with collaborators at British Columbia Cancer Agency and McMaster University. Trials address interventions evaluated against standards from organizations like NCCN and involve agents developed by pharmaceutical partners such as AstraZeneca, Pfizer, Roche, Merck, and biotech firms modeled on Genentech and Bristol-Myers Squibb. Methodological innovation includes adaptive designs influenced by statisticians from Johns Hopkins University and University of Pennsylvania.

Collaborations and Partnerships

The Group maintains partnerships with international cooperative groups including EORTC, ALLIANCE for Clinical Trials in Oncology, SWOG, and Groupement des Investigateurs Nationales (GID) style consortia, and works with regulatory and payer stakeholders like Health Canada and CADTH. Academic collaborations involve University of Toronto, McGill University, University of British Columbia, McMaster University, Université de Montréal, and international research centres such as MD Anderson Cancer Center and Dana-Farber Cancer Institute. Industry partnerships include alliances with Novartis, Eli Lilly and Company, GlaxoSmithKline, and patient advocacy links to Cancer Research UK and local charities like BC Cancer Foundation.

Funding and Resources

Core funding comes from grants awarded by bodies such as Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council for methods work, and program support from Canadian Cancer Society. Infrastructure support is provided through institutional budgets at Queen's University and partner hospitals including Princess Margaret Cancer Centre and BC Cancer. The Group accesses laboratory resources via collaborations with translational research laboratories at The Hospital for Sick Children and biostatistics cores modelled on units at Fred Hutchinson Cancer Research Center.

Impact and Contributions to Oncology

The Group has contributed to practice-changing evidence in areas such as adjuvant therapy, systemic chemotherapy regimens, and supportive care protocols used at centres like Princess Margaret Hospital, Jewish General Hospital, and BC Cancer. Results have informed guidelines produced by organizations including NCCN, ASCO, and provincial cancer agencies such as Cancer Care Ontario. Publications have appeared alongside reports from institutions like MD Anderson Cancer Center and have shaped health technology assessments by CADTH and reimbursement decisions by provincial formularies including Ontario Drug Benefit Program.

Notable Trials and Outcomes

Notable trials include randomized studies of systemic regimens in pancreatic cancer conducted with investigators from Toronto General Hospital and McMaster University, lung cancer trials that influenced use of targeted therapies developed by firms such as AstraZeneca and Roche with collaborators at Princess Margaret Cancer Centre and BC Cancer, and hematologic trials that advanced maintenance strategies evaluated with partners at The Ottawa Hospital and McGill University Health Centre. Supportive care outcomes addressing chemotherapy toxicity were implemented across networks exemplified by Sunnybrook Health Sciences Centre and St. Michael's Hospital, and translational biomarker substudies in partnership with laboratories at University Health Network and University of Calgary informed precision oncology approaches modeled after programs at Dana-Farber Cancer Institute.

Category:Cancer research organizations in Canada